Back

Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine

Bradley, T.; CODIEFY study team, ; Grundberg, E.; Selvarangan, R.

2021-02-05 infectious diseases
10.1101/2021.02.03.21251078 medRxiv
Show abstract

Current guidelines recommend that individuals who have had COVID-19 should receive the identical vaccine regimen as those who have not had the infection. This includes two doses of the mRNA platform vaccines (BNT162b2/Pfizer; mRNA-1273/Moderna) that are approved for use in the United States. In this brief report, we show that after a single dose of the Pfizer SARS-CoV-2 vaccine, individuals that had prior SARS-CoV-2 infection had significantly higher antibody levels than individuals that had no history of infection. This provides the rationale for changing vaccination policy to deliver only a single dose to individuals with recent SARS-CoV-2 infection that may free up additional doses for individuals that have no preexisting immunity to the virus. Future study of other immune parameters such as T cell response and durability of immune response should be rapidly undertaken in individuals that had COVID-19 prior to vaccination.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Clinical Infectious Diseases
◐ 235 papers in training set
Top 0.3%
7.7%
Similar papers in this journal
2
Med
○ 39 papers in training set
Top 0.1%
7.1%
Similar papers in this journal
3
Vaccine
○ 203 papers in training set
Top 0.6%
6.6%
Similar papers in this journal
4
The Journal of Infectious Diseases
◐ 202 papers in training set
Top 0.4%
6.1%
Similar papers in this journal
5
Nature Medicine
○ 125 papers in training set
Top 0.4%
5.3%
Similar papers in this journal
6
Science Translational Medicine
● 127 papers in training set
Top 0.5%
4.2%
7
Frontiers in Immunology
○ 638 papers in training set
Top 3%
4.2%
8
New England Journal of Medicine
● 52 papers in training set
Top 0.2%
3.9%
9
Cell Reports Medicine
○ 153 papers in training set
Top 0.8%
3.4%
10
JAMA
● 18 papers in training set
Top 0.1%
3.1%
50% of probability mass above
11
JAMA Network Open
● 130 papers in training set
Top 1%
3.1%
12
Open Forum Infectious Diseases
◐ 142 papers in training set
Top 1%
3.1%
13
npj Vaccines
○ 67 papers in training set
Top 0.3%
2.6%
14
Nature Communications
○ 5641 papers in training set
Top 40%
2.3%
15
Scientific Reports
○ 3612 papers in training set
Top 43%
2.3%
16
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.5%
2.1%
17
eBioMedicine
○ 183 papers in training set
Top 2%
2.1%
18
The Lancet Microbe
○ 44 papers in training set
Top 0.4%
1.9%
19
mBio
● 833 papers in training set
Top 8%
1.6%
20
Vaccines
○ 198 papers in training set
Top 2%
1.5%
21
Journal of Infection
○ 78 papers in training set
Top 0.7%
1.3%
22
Clinical & Translational Immunology
○ 22 papers in training set
Top 0.2%
1.1%
23
iScience
○ 1154 papers in training set
Top 28%
1.1%
24
Communications Medicine
○ 113 papers in training set
Top 3%
1.1%
25
JCI Insight
● 277 papers in training set
Top 6%
1.1%
26
Annals of Internal Medicine
● 28 papers in training set
Top 0.4%
1.1%
27
Emerging Infectious Diseases
● 105 papers in training set
Top 1%
1.1%
28
Nature
○ 645 papers in training set
Top 9%
1.0%
29
Cell Reports
○ 1498 papers in training set
Top 30%
0.6%
30
Nature Immunology
○ 79 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.